Aerie Pharma (AERI) Tops Q2 EPS by 11c

Aerie Pharma (NASDAQ: AERI) reported Q2 EPS of ($0.59), $0.11 better than the analyst estimate of ($0.70).

We expect a number of important clinical activities to take place during the third quarter of this year. Importantly, we anticipate the read-out of 90-day efficacy results for Rocket 2 this September. Additionally, preparations are well under way to launch our two new Phase 3 trials, Rocket 4 for RhopressaTM and Mercury 1 for RoclatanTM, both on track to start during the third quarter,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer.

Dr. Anido continued, “We continue to make excellent progress on our preclinical activities associated with the potential disease-modifying and neuroprotective properties of RhopressaTM and our wet AMD preclinical prospect, AR-13154. We expect to report on further findings later this year. Additionally, we remain focused on business development activities, including evaluating new ophthalmic product candidates and technologies to add to our pipeline, and we are very excited about the prospects for our new drug delivery collaboration with GrayBug.”

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Stantec (STN) Tops Q2 EPS by 47c
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c